Open Access Publishing and Subsequent Citations Among Articles in Major Cardiovascular Journals - 09/10/19
, Muthiah Vaduganathan, MD, MPH b, 1, Ramya C. Mosarla, MD c, Ramkumar V. Venkateswaran, MD b, Deepak L. Bhatt, MD, MPH b, Robert O. Bonow, MD, MS aAbstract |
Background |
While open access publishing among cardiovascular journals has increased in scope over the last decade, the relationship between open access and article citation volume remains unclear.
Methods |
We evaluated the association between open access publishing and citation number in 2017 among 4 major cardiovascular journals. Articles indexed to PubMed with ≥5 citations were identified among the following journals: Circulation, European Heart Journal, Journal of the American College of Cardiology, and JAMA Cardiology. Multivariable Poisson regression models were adjusted for journal and article type.
Results |
Of the 916 articles published in 2017, original investigations accounted for most articles (66.7%), followed by reviews (14.5%), guideline/scientific statements (8.4%), research letters (3.7%), viewpoints (3.7%), and editorials (2.9%). Among all articles, 43% (n = 391) were open access. Citation number was higher among open access articles compared with those with subscription access (14 [25th-75th percentile: 9-23] vs 11 [25th-75th percentile: 7-17]; P < .001). Open access status was significantly associated with higher number of citations after multivariable adjustment (β coefficient: +0.42; 95% confidence interval, 0.38-0.45, P < .001). Open access articles had consistently higher citations compared with subscription access articles across the 3 most frequent article types.
Conclusion |
Among contemporary articles published in major cardiovascular journals, open access publishing accounted for over 40% of articles and was significantly associated with increased short-term citations. Further research is required to assess the variation in long-term citation rates based on open access publishing status.
El texto completo de este artículo está disponible en PDF.Keywords : Cardiology, Citations, Journal, Open access, Publishing
| Funding: RP is supported by the National Heart, Lung, and Blood Institute T32 postdoctoral training grant (T32HL069771). |
|
| Conflict of Interest: MV is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Institutes of Health/National Center for Advancing Translational Sciences Award UL 1TR002541), and serves on advisory boards for Amgen, AstraZeneca, Bayer AG, and Baxter Healthcare. DLB discloses the following relationships - Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic, Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (COMPASS clinical trial steering committee funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), National Cardiovascular Data Registry-ACTION Registry Steering Committee (Chair), Veterans Affairs Clinical Assessment Reporting and Tracking Research and Publications Committee (Chair); Research Funding: Abbott, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Idorsia, Ironwood, Ischemix, Lilly, Medtronic, PhaseBio, Pfizer, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, PLx Pharma, Takeda. ROB serves as the Editor-in-Chief of JAMA Cardiology. The other authors report no relationships relevant to the contents of this paper to disclose. |
|
| Authorship: All authors had access to the data and had a role in writing the manuscript. |
Vol 132 - N° 9
P. 1103-1105 - septembre 2019 Regresar al número
Artículo precedente
- The Association of Peptic Ulcer Disease and Abdominal Aortic Aneurysm
- Oscar M.P. Jolobe
- AAIM Guidelines for Interview and Post-Interview Communication for Graduate Medical Education Recruitment
- Richard L. Alweis, Christopher M. Williams, Vera P. Luther, Debra L. Simmons, Richard Kopelman, Steven V. Angus, Solomon Liao, Sri Nagalla, Elaine A. Muchmore
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?